Inflectra

Infliximab, the active ingredient in Inflectra, is a monoclonal antibody (TNF‑alpha inhibitor) presented as a solution for infusion for intravenous use. It treats autoimmune and inflammatory conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

GNH USA supplies Inflectra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inflectra is a biologic that targets the TNF‑alpha pathway, providing disease‑modifying benefits across several inflammatory disorders. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Ankylosing spondylitis: improves spinal mobility and reduces pain. - Psoriatic arthritis: decreases joint damage and skin lesions. - Plaque psoriasis: clears skin plaques and reduces disease severity.

Inflectra may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions (fever, chills, flushing, dyspnea). - Upper respiratory tract infections. - Headache. - Nausea.

Serious or Rare Side Effects: - Severe infections such as tuberculosis, sepsis, or opportunistic fungal infections. - Hepatotoxicity, including elevated liver enzymes and hepatitis. - Malignancies, notably lymphoma and other solid tumors. - Exacerbation of congestive heart failure.

Before and during treatment with Inflectra, several safety measures should be observed. - Screening for latent TB: perform tuberculin skin test or interferon‑γ release assay prior to initiation. - Monitor for infections: promptly evaluate any signs of bacterial, viral, or fungal infection. - Assess liver function: conduct baseline and periodic hepatic enzyme tests. - Evaluate cardiac status: avoid use in patients with moderate to severe heart failure. - Vaccination: administer required vaccines before therapy; avoid live vaccines while receiving Inflectra. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Inflectra can interact with other medicines, influencing safety or effectiveness.

Major Interactions (Avoid): - Live vaccines: concurrent administration may cause uncontrolled infection. - Other potent immunosuppressants (e.g., azathioprine, cyclophosphamide): increase risk of serious infections. - Cytokine‑targeted agents (e.g., anakinra, canakinumab): additive immunosuppression may be hazardous.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, itraconazole): may raise infliximab serum levels. - Live bacterial vaccines (e.g., BCG): consider timing to avoid overlap. - Concomitant corticosteroids: may enhance infection risk; monitor closely.